Here are the 10-K annual reports from Pfizer Inc. (PFE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PFE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFE filings page.
Pfizer Inc. provides a comprehensive annual overview of its global biopharmaceutical business, strategy, risks and intellectual property. The company operates mainly through its Biopharma segment, supported by contract manufacturing (PC1), while winding down Pfizer Ignite.
Pfizer reports $25.5 billion of 2025 revenue from operations outside the U.S., representing 41% of total revenues, with China and Japan highlighted as key markets. It details major products and patent expirations through 2041, emphasizes oncology, vaccines, cardiometabolic and immunology R&D, and outlines 2026 priorities: maximizing key transactions, delivering critical R&D milestones, investing for post‑2028 growth, and scaling AI across the business.